share_log

Tempus AI | 8-K: Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics

Tempus AI | 8-K: Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics

Tempus AI | 8-K:Tempus 公布了 2024 年第三季度业绩并达成了收购 Ambry Genetics 的协议
美股SEC公告 ·  2024/11/04 13:06

Moomoo AI 已提取核心信息

Tempus AI reported strong Q3 2024 results with revenue increasing 33% YoY to $180.9M, driven by 64.4% growth in data services revenue and 23.9% growth in genomics testing volume. The company posted a net loss of $75.8M, including $22.2M in stock compensation expenses, while Adjusted EBITDA improved by $14.4M YoY to -$21.8M.The company announced plans to acquire Ambry Genetics for $600M, comprising $375M in cash and $225M in shares. Ambry, a leader in genetic testing, is expected to generate over $300M in revenue and $40M in EBITDA in 2024. The acquisition will be partially financed through a $300M debt increase from Ares.Tempus maintains its full-year 2024 guidance of approximately $700M in revenue, representing 32% YoY growth, and expects Adjusted EBITDA of -$105M, a $50M improvement over 2023. The company ended Q3 with $466.3M in cash and marketable securities.
Tempus AI reported strong Q3 2024 results with revenue increasing 33% YoY to $180.9M, driven by 64.4% growth in data services revenue and 23.9% growth in genomics testing volume. The company posted a net loss of $75.8M, including $22.2M in stock compensation expenses, while Adjusted EBITDA improved by $14.4M YoY to -$21.8M.The company announced plans to acquire Ambry Genetics for $600M, comprising $375M in cash and $225M in shares. Ambry, a leader in genetic testing, is expected to generate over $300M in revenue and $40M in EBITDA in 2024. The acquisition will be partially financed through a $300M debt increase from Ares.Tempus maintains its full-year 2024 guidance of approximately $700M in revenue, representing 32% YoY growth, and expects Adjusted EBITDA of -$105M, a $50M improvement over 2023. The company ended Q3 with $466.3M in cash and marketable securities.
Tempus 人工智能报告了2024年第三季度强劲的业绩,营业收入同比增长33%至18090万美金,得益于数据服务营业收入增长64.4%和基因组检测成交量增长23.9%。公司净亏损7580万美金,其中包括2220万美金的股票补偿费用,而调整后的息税折旧摊销前利润(EBITDA)同比改善1440万美金,达到-2180万美金。公司宣布计划以60000万美金收购Ambry Genetics,其中37500万美金为现金,22500万美金为股票。作为基因检测领域的领军者,Ambry预计在2024年会产生超过30000万美金的营业收入和4000万美金的EBITDA。此次收购将部分通过Ares提供的30000万美金的债务增加来融资。Tempus维持其2024年全年营业收入约70000万美金的指引,代表32%的同比增长,并预计调整后的EBITDA为-10500万美金,比2023年改善5000万美金。公司在第三季度结束时持有46630万美金的现金和可交易证券。
Tempus 人工智能报告了2024年第三季度强劲的业绩,营业收入同比增长33%至18090万美金,得益于数据服务营业收入增长64.4%和基因组检测成交量增长23.9%。公司净亏损7580万美金,其中包括2220万美金的股票补偿费用,而调整后的息税折旧摊销前利润(EBITDA)同比改善1440万美金,达到-2180万美金。公司宣布计划以60000万美金收购Ambry Genetics,其中37500万美金为现金,22500万美金为股票。作为基因检测领域的领军者,Ambry预计在2024年会产生超过30000万美金的营业收入和4000万美金的EBITDA。此次收购将部分通过Ares提供的30000万美金的债务增加来融资。Tempus维持其2024年全年营业收入约70000万美金的指引,代表32%的同比增长,并预计调整后的EBITDA为-10500万美金,比2023年改善5000万美金。公司在第三季度结束时持有46630万美金的现金和可交易证券。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息